- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.01. | XUANZHUBIO-B (02575): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 05.01. | XUANZHUBIO-B (02575): APPOINTMENT OF GENERAL MANAGER | - | HKEx | ||
| 02.01. | XUANZHUBIO-B (02575): RESIGNATION OF EXECUTIVE DIRECTOR AND GENERAL MANAGER | - | HKEx | ||
| 08.12.25 | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT SUCCESSFUL RENEWAL AND INCLUSION OF THE INNOVATIVE DRUG ANJIUWEI IN THE 2025 NRDL | 1 | HKEx | ||
| 08.12.25 | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT XUANYUENING, AN INNOVATIVE DRUG, FIRST INCLUDED IN THE NRDL | 5 | HKEx | ||
| 20.11.25 | XUANZHUBIO-B (02575): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| XUANZHU BIOPHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 20.11.25 | XUANZHUBIO-B (02575): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS | 2 | HKEx | ||
| 17.11.25 | XUANZHUBIO-B (02575): INSIDE INFORMATION FILING WITH THE CSRC FOR PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | 1 | HKEx | ||
| 14.11.25 | XUANZHUBIO-B (02575): INSIDE INFORMATION PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | - | HKEx | ||
| 28.10.25 | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT NG-350A GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA | - | HKEx | ||
| 22.10.25 | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT OF PHASE III CLINICAL STUDY DATA OF BIREOCICLIB FOR FIRST-LINE TREATMENT OF HR+/HER2 - ADVANCED ... | 2 | HKEx | ||
| 15.10.25 | SIHUAN PHARM (00460): UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF XUANZHU BIOPHARM ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED ... | 1 | HKEx | ||
| 14.10.25 | XUANZHUBIO-B (02575): ANNOUNCEMENT OF ALLOTMENT RESULTS | - | HKEx | ||
| 14.10.25 | XUANZHUBIO-B (02575): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 14.10.25 | XUANZHUBIO-B (02575): TERMS OF REFERENCE AND RULES OF PROCEDURE OF THE NOMINATION COMMITTEE OF THE BOARD | 2 | HKEx | ||
| 14.10.25 | XUANZHUBIO-B (02575): TERMS OF REFERENCE AND RULES OF PROCEDURE OF THE REMUNERATION AND APPRAISAL COMMITTEE OF THE BOARD | 1 | HKEx | ||
| 14.10.25 | XUANZHUBIO-B (02575): TERMS OF REFERENCE AND RULES OF PROCEDURE OF THE AUDIT COMMITTEE OF THE BOARD | 1 | HKEx | ||
| 14.10.25 | XUANZHUBIO-B (02575): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 06.10.25 | SIHUAN PHARM (00460): UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF XUANZHU BIOPHARM ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED ... | - | HKEx | ||
| 06.10.25 | XUANZHUBIO-B (02575): GLOBAL OFFERING | 3 | HKEx |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 48,000 | +22,28 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Qiagen beim fairen Aktienwert von 50 Euro auf "Kaufen" belassen. Der Diagnostikspezialist habe seine Mittelfristziele für Wachstumstreiber... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 324,08 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy | BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company... ► Artikel lesen | |
| ARCELLX | 72,17 | 0,00 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| APOGEE THERAPEUTICS | 82,04 | +1,57 % | Apogee Therapeutics auf Rekordhoch: Aktie erreicht 81,0 USD | ||
| COGENT BIOSCIENCES | 39,900 | +2,47 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 70,93 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 90,85 | 0,00 % | Guggenheim raises Structure Therapeutics stock price target to $140 on obesity drug confidence | ||
| NURIX THERAPEUTICS | 18,240 | 0,00 % | BTIG reiterates Buy rating on Nurix stock with $30 price target | ||
| BEAM THERAPEUTICS | 30,965 | 0,00 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 12,120 | 0,00 % | Day One Biopharmaceuticals stock initiated with Buy rating at TD Cowen | ||
| NUVALENT | 105,93 | 0,00 % | Nuvalent, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,395 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| ALUMIS | 26,050 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| ERASCA | 9,805 | 0,00 % | Erasca (ERAS) Soars 42% on Bullish Rating, PT Upgrade | ||
| IMMUNITYBIO | 5,500 | +0,59 % | ImmunityBio-Aktie: Jetzt noch mit der Kursrakete mitfliegen? | Die ImmunityBio-Aktie machte einen Raketenstart ins neue Jahr. Bis gestern schoss der Kurs des Biotech-Unternehmens von 2,00 auf 5,50 US$ hoch. Doch am Dienstagmorgen bricht der Biotech-Titel im europäischen... ► Artikel lesen |
Das Unternehmen XUANZHU BIOPHARMACEUTICAL CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XUANZHU BIOPHARMACEUTICAL CO LTD finden Sie auf Wallstreet Online.